Loading clinical trials...
Loading clinical trials...
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only.
This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes mellitus treated with diet and exercise only.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Novo Nordisk Investigational Site
Lancaster, California, United States
Novo Nordisk Investigational Site
Los Angeles, California, United States
Novo Nordisk Investigational Site
Montclair, California, United States
Novo Nordisk Investigational Site
North Hollywood, California, United States
Novo Nordisk Investigational Site
Riverside, California, United States
Novo Nordisk Investigational Site
San Diego, California, United States
Novo Nordisk Investigational Site
San Jose, California, United States
Novo Nordisk Investigational Site
San Mateo, California, United States
Novo Nordisk Investigational Site
Doral, Florida, United States
Novo Nordisk Investigational Site
Hialeah, Florida, United States
Start Date
September 20, 2016
Primary Completion Date
October 30, 2017
Completion Date
December 8, 2017
Last Updated
July 20, 2022
703
ACTUAL participants
semaglutide
DRUG
placebo
DRUG
Lead Sponsor
Novo Nordisk A/S
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07296484